JP2016521755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521755A5 JP2016521755A5 JP2016519696A JP2016519696A JP2016521755A5 JP 2016521755 A5 JP2016521755 A5 JP 2016521755A5 JP 2016519696 A JP2016519696 A JP 2016519696A JP 2016519696 A JP2016519696 A JP 2016519696A JP 2016521755 A5 JP2016521755 A5 JP 2016521755A5
- Authority
- JP
- Japan
- Prior art keywords
- metabolic disorder
- composition
- antagonist
- major component
- sumn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 7
- 102000003678 AMPA Receptors Human genes 0.000 claims description 4
- 108090000078 AMPA Receptors Proteins 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims 31
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 22
- 239000000774 AMPA receptor agonist Substances 0.000 claims 14
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 claims 12
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 claims 12
- 229940124118 AMPA receptor agonist Drugs 0.000 claims 11
- 229960003638 dopamine Drugs 0.000 claims 9
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 7
- 208000001280 Prediabetic State Diseases 0.000 claims 7
- 235000020824 obesity Nutrition 0.000 claims 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 6
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 6
- 210000005064 dopaminergic neuron Anatomy 0.000 claims 5
- 230000008499 blood brain barrier function Effects 0.000 claims 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 230000033764 rhythmic process Effects 0.000 claims 4
- 230000037007 arousal Effects 0.000 claims 3
- 230000003371 gabaergic effect Effects 0.000 claims 3
- 210000000221 suprachiasmatic nucleus Anatomy 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000006742 locomotor activity Effects 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 206010062519 Poor quality sleep Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002445 nipple Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000002618 waking effect Effects 0.000 claims 1
- -1 amide phosphate derivatives Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- SULXXKLCQRXMHP-UHFFFAOYSA-N 4-[1-hydroxy-5-(3-phenylphenyl)pyrazol-4-yl]piperidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC(C=2C=CC=CC=2)=CC=1C=1N(O)N=CC=1C1CCNCC1 SULXXKLCQRXMHP-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 2
- OMCYEZUIYGPHDJ-OQLLNIDSSA-N chembl354261 Chemical compound OC1=CC=CC=C1\C=N\NC(=O)C1=CC=CC=C1O OMCYEZUIYGPHDJ-OQLLNIDSSA-N 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 2
- RLJKFAMYSYWMND-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;chloride Chemical compound [Cl-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 RLJKFAMYSYWMND-GRTNUQQKSA-M 0.000 description 1
- HKJKCPKPSSVUHY-GRTNUQQKSA-M (6r)-6-[(5s)-6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl]-6h-furo[3,4-g][1,3]benzodioxol-8-one;iodide Chemical compound [I-].O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CC[N+]2(C)C)C(=O)C2=C1C=CC1=C2OCO1 HKJKCPKPSSVUHY-GRTNUQQKSA-M 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- IAWXTSMHXFRLQR-UHFFFAOYSA-N 2,3-bis($l^{1}-oxidanyl)-7-nitroquinoxaline-6-carbonitrile Chemical compound O=C1C(=O)N=C2C=C(C#N)C([N+](=O)[O-])=CC2=N1 IAWXTSMHXFRLQR-UHFFFAOYSA-N 0.000 description 1
- ZZYJIEWWTWIQGM-UHFFFAOYSA-N 3-ethoxy-4-[4-[3-(propan-2-ylsulfonylamino)thiophen-2-yl]phenyl]benzoic acid Chemical compound CCOC1=CC(C(O)=O)=CC=C1C1=CC=C(C2=C(C=CS2)NS(=O)(=O)C(C)C)C=C1 ZZYJIEWWTWIQGM-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- BWXCECYGGMGBHD-UHFFFAOYSA-M 6-(6,6-dimethyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-5-yl)-6h-furo[3,4-g][1,3]benzodioxol-8-one;bromide Chemical compound [Br-].C[N+]1(C)CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 BWXCECYGGMGBHD-UHFFFAOYSA-M 0.000 description 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 1
- 239000000775 AMPA receptor antagonist Substances 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 229940098788 GABA receptor antagonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- PIMZUZSSNYHVCU-OMKDEKJRSA-N Picrotoxinin Natural products O=C1O[C@@H]2[C@@H](C(=C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@H]2C1 PIMZUZSSNYHVCU-OMKDEKJRSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IYGYMKDQCDOMRE-ZWKOTPCHSA-N bicuculline Chemical compound O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-ZWKOTPCHSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- SHLPPXXKRFINFY-UHFFFAOYSA-N isoquinolin-2-ium;bromide Chemical compound Br.C1=NC=CC2=CC=CC=C21 SHLPPXXKRFINFY-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- PIMZUZSSNYHVCU-YKWPQBAZSA-N picrotoxinin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2 PIMZUZSSNYHVCU-YKWPQBAZSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 150000008334 thiadiazines Chemical class 0.000 description 1
- USMNOWBWPHYOEA-MRTMQBJTSA-N α-thujone Chemical compound O=C([C@@H]1C)C[C@@]2(C(C)C)[C@@H]1C2 USMNOWBWPHYOEA-MRTMQBJTSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361834864P | 2013-06-13 | 2013-06-13 | |
| US61/834,864 | 2013-06-13 | ||
| PCT/US2014/042397 WO2014201411A1 (en) | 2013-06-13 | 2014-06-13 | Compositions and methods for treating metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521755A JP2016521755A (ja) | 2016-07-25 |
| JP2016521755A5 true JP2016521755A5 (OSRAM) | 2017-07-27 |
Family
ID=52022819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519696A Pending JP2016521755A (ja) | 2013-06-13 | 2014-06-13 | 代謝障害を治療するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20150011554A1 (OSRAM) |
| EP (2) | EP3008167A4 (OSRAM) |
| JP (1) | JP2016521755A (OSRAM) |
| CN (1) | CN105579575A (OSRAM) |
| AU (1) | AU2014277952A1 (OSRAM) |
| BR (1) | BR112015031249A2 (OSRAM) |
| CA (1) | CA2915405A1 (OSRAM) |
| MX (1) | MX2015017253A (OSRAM) |
| WO (1) | WO2014201411A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| EP3524248A1 (en) | 2007-06-21 | 2019-08-14 | VeroScience LLC | Method of treating metabolic disorders and depression with dopamine receptor agonists |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| WO2017184875A1 (en) | 2016-04-20 | 2017-10-26 | Veroscience Llc | Composition and method for treating metabolic disorders |
| DK3697418T3 (da) | 2017-10-18 | 2024-10-07 | Veroscience Llc | Forbedrede formuleringer af bromocriptin |
| US20200397751A1 (en) * | 2017-12-05 | 2020-12-24 | Peter Vanderklish | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia |
| US12343359B2 (en) | 2019-05-23 | 2025-07-01 | Dignity Health | Inhibitory interneuron treatment methods, uses and compositions for diabetes |
| WO2021061818A1 (en) | 2019-09-23 | 2021-04-01 | Veroscience Llc | Method for inducing tumor regression |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784703A (en) * | 1972-02-29 | 1974-01-08 | Merck & Co Inc | Method of treating hypertension |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US4933324A (en) | 1988-02-26 | 1990-06-12 | Shashoua Victor E | Fatty acid-neuroactive drug conjugate as a prodrug |
| US4939174A (en) | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5344832A (en) * | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| RU2104698C1 (ru) * | 1991-12-23 | 1998-02-20 | Дзе Борд оф Сьюпервайзорз оф Луизиана Стейт Юниверсити энд Эгрикалчурал энд Мекэникал Колледж | Способ лечения патологических отклонений при диабете типа ii |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| DK0651746T3 (da) | 1992-07-24 | 2002-07-29 | Univ California | Lægemidler, der forbedrer synaptiske responser medieret af AMPA-receptorer |
| US6274600B1 (en) | 1995-06-05 | 2001-08-14 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic responses mediated by AMPA receptors |
| US20020099050A1 (en) | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US5488049A (en) | 1993-12-10 | 1996-01-30 | Fidia - Georgetown Institute For The Neuro-Sciences | Method of treating learning and memory disorders using benzothiadiazide derivatives as nootropic agents |
| US5852008A (en) | 1995-01-24 | 1998-12-22 | The Regents Of The University Of California | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5773434A (en) | 1995-08-30 | 1998-06-30 | Gary A. Rogers | Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
| US5686423A (en) * | 1996-02-16 | 1997-11-11 | Department Of Health, The Executive Yuan, Republic Of China | Di-and tri-peptide mimetic compounds for Parkinson's disease |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| AU4416197A (en) | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
| WO1998012185A1 (en) | 1996-09-17 | 1998-03-26 | The Regents Of The University Of California | Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor |
| AU5106498A (en) * | 1996-10-22 | 1998-05-15 | Ergo Research Corporation | Method for increasing blood insulin levels in mammals |
| GB9702194D0 (en) | 1997-02-04 | 1997-03-26 | Lilly Co Eli | Sulphonide derivatives |
| US6110935A (en) | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| US20050245612A1 (en) * | 2004-05-03 | 2005-11-03 | Blass John P | Pharmaceutical compositions for metabolic insufficiencies |
| US5985871A (en) | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| PL342843A1 (en) | 1998-02-18 | 2001-07-16 | Neurosearch As | Novel compounds and their use as positive ampa receptor modulators |
| US6943159B1 (en) | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
| WO1999043285A2 (en) | 1998-02-24 | 1999-09-02 | Eli Lilly And Company | Sulphonamide derivatives |
| US6174922B1 (en) | 1998-05-11 | 2001-01-16 | Eli Lilly And Company | Sulphonamide derivatives |
| EP1066039A4 (en) | 1998-03-02 | 2003-02-26 | Cocensys Inc | SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES |
| US6107489A (en) | 1998-03-17 | 2000-08-22 | Conjuchem, Inc. | Extended lifetimes in vivo renin inhibitors |
| US6124278A (en) | 1998-04-03 | 2000-09-26 | The Regents Of The University Of California | Acylbenzoxazines for enhancing synaptic response |
| AU3879899A (en) * | 1998-05-04 | 1999-11-23 | Neotherapeutics, Inc. | Novel dopamine-like 9-substituted hypoxanthine and methods of use |
| CA2338862A1 (en) | 1998-07-31 | 2000-02-10 | Dennis Michael Zimmerman | Alkenyl sulphonamide derivatives |
| US6358981B1 (en) | 1998-07-31 | 2002-03-19 | Eli Lilly And Company | Sulphonamide derivatives |
| PE20000944A1 (es) | 1998-07-31 | 2000-09-20 | Lilly Co Eli | Derivados de sulfonamida |
| US6617351B1 (en) | 1998-07-31 | 2003-09-09 | Eli Lilly And Company | Amide, carbamate, and urea derivatives |
| PE20000942A1 (es) | 1998-07-31 | 2000-09-28 | Lilly Co Eli | Derivados de amida, carbamato y urea |
| PE20000943A1 (es) | 1998-07-31 | 2000-09-28 | Lilly Co Eli | Derivados de sulfonamida |
| US6500865B1 (en) | 1998-07-31 | 2002-12-31 | Eli Lilly And Company | Sulfonamide derivatives |
| EP1100497B1 (en) | 1998-07-31 | 2004-05-12 | Eli Lilly And Company | Heterocyclyl sulphonamide derivatives |
| US6552086B1 (en) | 1998-07-31 | 2003-04-22 | Eli Lilly And Company | Sulfonamide derivatives |
| JP2002521445A (ja) | 1998-07-31 | 2002-07-16 | イーライ・リリー・アンド・カンパニー | 複素環スルホンアミド誘導体 |
| WO2000006176A1 (en) | 1998-07-31 | 2000-02-10 | Eli Lilly And Company | Amidophosphate derivatives |
| AU5235599A (en) | 1998-07-31 | 2000-02-21 | Eli Lilly And Company | N-substituted sulfonamide derivatives |
| WO2000066546A2 (en) | 1999-04-30 | 2000-11-09 | Eli Lilly And Company | Monofluoroalkyl derivatives |
| WO2000075123A1 (en) | 1999-06-04 | 2000-12-14 | Euro-Celtique S.A. | Substituted 5-oxo-5,6,7,8-tetrahydro-4h-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of ampa |
| US6297226B1 (en) | 1999-10-15 | 2001-10-02 | Neotherapeutics, Inc. | Synthesis and methods of use of 9-substituted guanine derivatives |
| US6639107B1 (en) | 1999-12-08 | 2003-10-28 | Eli Lilly And Company | Cyclopentyl sulfonamide derivatives |
| DE60039631D1 (de) | 1999-12-08 | 2008-09-04 | Lilly Co Eli | Cyclopentyl sulfonamid derivaten |
| DE10004572A1 (de) | 2000-02-02 | 2001-08-09 | Boehringer Ingelheim Pharma | Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| JP2003527369A (ja) | 2000-03-13 | 2003-09-16 | イーライ・リリー・アンド・カンパニー | スルホンアミド誘導体 |
| US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
| KR20030007644A (ko) | 2000-05-19 | 2003-01-23 | 일라이 릴리 앤드 캄파니 | 술폰아미드 유도체 |
| MXPA02010021A (es) | 2000-05-19 | 2003-02-12 | Lilly Co Eli | Derivados de sulfonamida. |
| EP1292571A2 (en) | 2000-06-06 | 2003-03-19 | Eli Lilly And Company | (bis)sulfonamide derivatives |
| ATE272617T1 (de) | 2000-06-13 | 2004-08-15 | Lilly Co Eli | Sulfonamid-derivate |
| EP1309577A2 (en) | 2000-08-11 | 2003-05-14 | Eli Lilly And Company | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function |
| WO2002014275A2 (en) | 2000-08-11 | 2002-02-21 | Eli Lilly And Company | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function |
| WO2002018329A1 (en) | 2000-08-31 | 2002-03-07 | Eli Lilly And Company | Acetylenic sulfonamide derivatives |
| JP2004511540A (ja) | 2000-10-13 | 2004-04-15 | イーライ・リリー・アンド・カンパニー | シクロアルキルフルオロスルホンアミド誘導体 |
| AU2001235976A1 (en) * | 2000-12-19 | 2002-07-01 | Malladi Surya Prakasa Sastry | An antidiabetic composition of amino acids |
| CA2446161A1 (en) * | 2001-05-04 | 2002-11-14 | Emanuele Sher | Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes |
| ITBO20010271A1 (it) | 2001-05-08 | 2002-11-08 | Giuseppe Cannazza | Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl |
| US20030100552A1 (en) | 2001-05-17 | 2003-05-29 | Boehringer Ingelheim Pharma Kg | Positive allosteric AMPA receptor modulators (PAARM), processes for preparing them, and their use as pharmaceutical compositions |
| ATE298742T1 (de) | 2001-05-30 | 2005-07-15 | Lilly Co Eli | Zykloalkenylsulfonamidderivate |
| EP1409452A1 (en) | 2001-06-05 | 2004-04-21 | Eli Lilly And Company | Sulfonamide derivatives |
| TWI232863B (en) | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
| WO2003011270A1 (de) * | 2001-07-31 | 2003-02-13 | Lothar Saiger | Mittel zur behandlung von depressionen enthaltend ein lokalanästhetikum |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| HUP0402279A3 (en) | 2001-11-26 | 2008-09-29 | Cortex Pharmaceuticals | Heterocondensated benzo[e][1,3]oxazin-4-one compounds for enhancing glutamatergic synaptic responses and pharmaceutical compositions containing them |
| WO2004009665A2 (en) * | 2002-07-19 | 2004-01-29 | The Regents Of The University Of California | Dendrimers as molecular translocators |
| US9655865B2 (en) * | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20080200453A1 (en) * | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20050054652A1 (en) * | 2002-07-29 | 2005-03-10 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| FR2854634B1 (fr) | 2003-05-05 | 2005-07-08 | Servier Lab | Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7625932B2 (en) | 2003-10-08 | 2009-12-01 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| GB0407583D0 (en) * | 2004-04-05 | 2004-05-05 | Arbab Tarig S M | Diagnostic testing and related matters |
| WO2005110394A1 (ja) * | 2004-05-19 | 2005-11-24 | Ajinomoto Co., Inc. | 糖尿病治療薬 |
| MX339690B (es) | 2004-06-04 | 2016-06-06 | Xenoport Inc | Profarmacos de levodopa y sus composiciones y usos. |
| US20070270471A1 (en) | 2004-08-09 | 2007-11-22 | Glaxo Group Limited | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine |
| CN101035760B (zh) | 2004-08-09 | 2011-03-02 | 葛兰素集团有限公司 | 增强谷氨酸受体的化合物及其在药物中的应用 |
| GB0417709D0 (en) | 2004-08-09 | 2004-09-08 | Glaxo Group Ltd | Compounds |
| US20060167099A1 (en) * | 2004-11-09 | 2006-07-27 | Anat Biegon | Use of compositions that increase glutamate receptor activity in treatment of brain injury |
| ATE517867T1 (de) | 2005-02-15 | 2011-08-15 | Glaxo Group Ltd | Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin |
| CA2642429A1 (en) * | 2005-02-17 | 2006-08-24 | Instituto Del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
| DE602006003661D1 (de) | 2005-06-06 | 2008-12-24 | Lilly Co Eli | Ampa-rezeptoren-verstärker |
| US20090305225A1 (en) * | 2005-06-13 | 2009-12-10 | Galbraith Richard A | Inhibition of Creatine Uptake to Promote Weight Loss |
| CN101370488B (zh) * | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| WO2007060144A2 (en) | 2005-11-22 | 2007-05-31 | Neurosearch A/S | Novel quinoxaline derivatives and their medical use |
| GB0602560D0 (en) | 2006-02-08 | 2006-03-22 | Glaxo Group Ltd | Compounds |
| WO2007090840A1 (en) | 2006-02-08 | 2007-08-16 | Glaxo Group Limited | 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia |
| WO2008076458A1 (en) | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| US7829592B2 (en) | 2006-12-21 | 2010-11-09 | Xenoport, Inc. | Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| GB0711088D0 (en) * | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| GB0721092D0 (en) * | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| GB0721094D0 (en) * | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| WO2009114718A2 (en) * | 2008-03-12 | 2009-09-17 | University Of Miami | Methods and assays for detecting and treating hypoglycemia |
| WO2010015037A1 (en) * | 2008-08-08 | 2010-02-11 | Howard Florey Institute | Therapeutic methods and compositions |
| US8399513B2 (en) | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| GB0821166D0 (en) * | 2008-11-19 | 2008-12-24 | Glaxo Group Ltd | Compounds |
| GB0822425D0 (en) * | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Compounds |
| WO2010121023A2 (en) * | 2009-04-15 | 2010-10-21 | The Regents Of The University Of California | Peptides and aptamers for targeting of neuron or nerves |
| US10206921B2 (en) | 2009-06-03 | 2019-02-19 | The Regents Of The University Of California | Methods and compositions for treating a subject for central nervous system (CNS) injury |
| WO2011053869A2 (en) * | 2009-10-31 | 2011-05-05 | The Regents Of The University Of California | Manipulation of brain in a circuit-specific manner |
| KR101852215B1 (ko) * | 2010-08-10 | 2018-04-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 및 이의 용도 |
| US8697898B2 (en) | 2011-11-23 | 2014-04-15 | Instytut Medycyny Doswiadczalnej i Klinicznej im. M. Mossakowskiego PAN | Medical application of lipid derivatives of dopamine and the methods of their production |
-
2014
- 2014-06-13 JP JP2016519696A patent/JP2016521755A/ja active Pending
- 2014-06-13 US US14/304,659 patent/US20150011554A1/en not_active Abandoned
- 2014-06-13 WO PCT/US2014/042397 patent/WO2014201411A1/en not_active Ceased
- 2014-06-13 BR BR112015031249A patent/BR112015031249A2/pt not_active Application Discontinuation
- 2014-06-13 EP EP14811295.6A patent/EP3008167A4/en not_active Withdrawn
- 2014-06-13 AU AU2014277952A patent/AU2014277952A1/en not_active Abandoned
- 2014-06-13 CN CN201480044899.5A patent/CN105579575A/zh active Pending
- 2014-06-13 EP EP17206128.5A patent/EP3311842A1/en not_active Withdrawn
- 2014-06-13 MX MX2015017253A patent/MX2015017253A/es unknown
- 2014-06-13 CA CA2915405A patent/CA2915405A1/en not_active Abandoned
-
2018
- 2018-11-16 US US16/193,193 patent/US20190160059A1/en not_active Abandoned
-
2022
- 2022-01-04 US US17/568,560 patent/US20220142960A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521755A5 (OSRAM) | ||
| JP4850880B2 (ja) | 疼痛の処置のためのエピナスチンの使用 | |
| CN108883108B (zh) | 马赛替尼用于治疗肌萎缩侧索硬化症患者亚群的用途 | |
| AU2016226006B2 (en) | Method of treatment with tradipitant | |
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2013505983A5 (OSRAM) | ||
| RU2008150622A (ru) | Лечение агонистом мелатонина | |
| JP2010526837A5 (OSRAM) | ||
| US20200383983A1 (en) | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo | |
| JP2018522920A5 (OSRAM) | ||
| ES2383433T3 (es) | Formulación farmacéutica de apomorfina para administración bucal | |
| CA3152384A1 (en) | Method of treating a sleep breathing disorder | |
| BR112019020100A2 (pt) | composições e métodos para tratar sinucleinopatias | |
| JP2016505050A5 (OSRAM) | ||
| Arima et al. | Positive effect of baclofen on body weight reduction in obese subjects: a pilot study | |
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| CA2963179C (en) | Levosimendan for use in the treatment of motor neuron diseases (als) | |
| Zesiewicz et al. | Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease | |
| Minton | Volunteer models for predicting antiemetic activity of 5‐HT3‐receptor antagonists. | |
| US6489356B2 (en) | Method for treating pain in humans | |
| CA2932200A1 (en) | Treatment of spasticity with intrathecal dantrolene | |
| BR112020016672A2 (pt) | Leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma e método de reduzir, inibir ou eliminar um ou mais sintomas de síndrome das pernas inquietas (rls) em um indivíduo em necessidade do mesmo | |
| JP2020527156A5 (OSRAM) | ||
| BR112019022175A2 (pt) | Composições e método para tratamento de depressão | |
| Serafini et al. | The use of rotigotine in the treatment of restless legs syndrome |